CN1206213C - N-芳基磺酰氨基酸ω-酰胺 - Google Patents

N-芳基磺酰氨基酸ω-酰胺 Download PDF

Info

Publication number
CN1206213C
CN1206213C CNB998129321A CN99812932A CN1206213C CN 1206213 C CN1206213 C CN 1206213C CN B998129321 A CNB998129321 A CN B998129321A CN 99812932 A CN99812932 A CN 99812932A CN 1206213 C CN1206213 C CN 1206213C
Authority
CN
China
Prior art keywords
alkyl
formula
hydrogen atom
compound
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB998129321A
Other languages
English (en)
Chinese (zh)
Other versions
CN1332724A (zh
Inventor
W·施瓦布
W·索瓦特
M·舒多克
B·哈斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis Deutschland GmbH
Original Assignee
Aventis Pharma Deutschland GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Deutschland GmbH filed Critical Aventis Pharma Deutschland GmbH
Publication of CN1332724A publication Critical patent/CN1332724A/zh
Application granted granted Critical
Publication of CN1206213C publication Critical patent/CN1206213C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C07C311/19—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Indole Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
CNB998129321A 1998-11-06 1999-10-21 N-芳基磺酰氨基酸ω-酰胺 Expired - Fee Related CN1206213C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19851184A DE19851184A1 (de) 1998-11-06 1998-11-06 N-Arylsulfonyl-aminosäure-omega-amide
DE19851184.1 1998-11-06

Publications (2)

Publication Number Publication Date
CN1332724A CN1332724A (zh) 2002-01-23
CN1206213C true CN1206213C (zh) 2005-06-15

Family

ID=7886902

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB998129321A Expired - Fee Related CN1206213C (zh) 1998-11-06 1999-10-21 N-芳基磺酰氨基酸ω-酰胺

Country Status (23)

Country Link
US (2) US6201130B1 (cg-RX-API-DMAC7.html)
EP (1) EP1124797B1 (cg-RX-API-DMAC7.html)
JP (1) JP4348014B2 (cg-RX-API-DMAC7.html)
KR (1) KR100655632B1 (cg-RX-API-DMAC7.html)
CN (1) CN1206213C (cg-RX-API-DMAC7.html)
AR (1) AR021086A1 (cg-RX-API-DMAC7.html)
AT (1) ATE260889T1 (cg-RX-API-DMAC7.html)
AU (1) AU757602B2 (cg-RX-API-DMAC7.html)
BR (1) BR9915729A (cg-RX-API-DMAC7.html)
CA (1) CA2350031C (cg-RX-API-DMAC7.html)
CZ (1) CZ302291B6 (cg-RX-API-DMAC7.html)
DE (2) DE19851184A1 (cg-RX-API-DMAC7.html)
DK (1) DK1124797T3 (cg-RX-API-DMAC7.html)
ES (1) ES2213405T3 (cg-RX-API-DMAC7.html)
HK (1) HK1041686B (cg-RX-API-DMAC7.html)
HU (1) HUP0104122A3 (cg-RX-API-DMAC7.html)
ID (1) ID28810A (cg-RX-API-DMAC7.html)
PL (1) PL198827B1 (cg-RX-API-DMAC7.html)
PT (1) PT1124797E (cg-RX-API-DMAC7.html)
RU (1) RU2228330C2 (cg-RX-API-DMAC7.html)
TR (1) TR200101245T2 (cg-RX-API-DMAC7.html)
WO (1) WO2000027808A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200103485B (cg-RX-API-DMAC7.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003042190A1 (en) 2001-11-12 2003-05-22 Pfizer Products Inc. N-alkyl-adamantyl derivatives as p2x7-receptor antagonists
PA8557501A1 (es) 2001-11-12 2003-06-30 Pfizer Prod Inc Benzamida, heteroarilamida y amidas inversas
US7071223B1 (en) * 2002-12-31 2006-07-04 Pfizer, Inc. Benzamide inhibitors of the P2X7 receptor
PA8591801A1 (es) 2002-12-31 2004-07-26 Pfizer Prod Inc Inhibidores benzamidicos del receptor p2x7.
MXPA05010165A (es) * 2003-04-15 2005-11-16 Warner Lambert Co Derivados de prolina biciclicos [c]-condensados y su uso para el tratamiento de estados artriticos.
EP1626962B1 (en) * 2003-05-12 2007-02-28 Pfizer Products Inc. Benzamide inhibitors of the p2x7 receptor
CN1980902A (zh) * 2004-06-29 2007-06-13 辉瑞产品有限公司 通过对羟基保护前体去保护而制备5-4-(2-羟基-丙基)-3,5-二氧代-4,5-二氢-3h-[1,2,4]三嗪-2-基-苯甲酰胺衍生物的方法
CA2572118A1 (en) * 2004-06-29 2006-01-12 Pfizer Products Inc. Method for preparing 5-`4-(2-hydroxy-ethyl)-3,5-dioxo-4,5-dihydro-3h-`1,2,4!-triazin-2-yl!benzamide derivatives with p2x7 inhibiting activity by reaction of the derivative unsubstituted in 4-position of the triazine with an oxiran in the presence of a lewis acid
BRPI0512915A (pt) * 2004-06-29 2008-04-15 Warner Lambert Co terapias de combinação utilizando inibidores benzamida do receptor p2x7
US7576222B2 (en) 2004-12-28 2009-08-18 Wyeth Alkynyl-containing tryptophan derivative inhibitors of TACE/matrix metalloproteinase
MY144590A (en) 2005-07-11 2011-10-14 Wyeth Corp Glutamate aggrecanase inhibitors
KR20080058436A (ko) 2005-10-13 2008-06-25 와이어쓰 글루탐산 유도체의 제조 방법
WO2012004743A1 (en) 2010-07-09 2012-01-12 Pfizer Limited Benzenesulfonamides useful as sodium channel inhibitors
EP2953932B1 (en) * 2013-02-06 2017-03-01 Merck Patent GmbH Substituted carboxylic acid derivatives as aggrecanase inhibitors for the treatment of osteoarthritis

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU1063026A1 (ru) * 1982-05-19 1990-12-07 Институт биохимии АН ЛитССР N @ -Бензолсульфонильные производные трес-DL-фенилсерина, обладающие противовоспалительной активностью
JP2764262B2 (ja) 1987-08-28 1998-06-11 持田製薬株式会社 ヒダントイン誘導体及びそれを有効成分とする医薬組成物
TW201303B (cg-RX-API-DMAC7.html) 1990-07-05 1993-03-01 Hoffmann La Roche
US5455258A (en) * 1993-01-06 1995-10-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids
AU690703B2 (en) 1994-06-22 1998-04-30 British Biotech Pharmaceuticals Limited Metalloproteinase inhibitors
US5863949A (en) * 1995-03-08 1999-01-26 Pfizer Inc Arylsulfonylamino hydroxamic acid derivatives
EP0837901A1 (en) * 1995-06-28 1998-04-29 E.I. Du Pont De Nemours And Company Fluoropolymer nanocomposites
KR980009238A (ko) 1995-07-28 1998-04-30 우에노 도시오 설포닐아미노산 유도체
CZ294063B6 (cs) * 1996-05-17 2004-09-15 Warner-Lambert Company Bifenylsulfonamid, jeho použití a farmaceutický prostředek s jeho obsahem
DE19719621A1 (de) * 1997-05-09 1998-11-12 Hoechst Ag Sulfonylaminocarbonsäuren

Also Published As

Publication number Publication date
AU757602B2 (en) 2003-02-27
DK1124797T3 (da) 2004-07-05
ES2213405T3 (es) 2004-08-16
HK1041686B (zh) 2005-09-23
EP1124797A1 (de) 2001-08-22
ZA200103485B (en) 2001-12-04
JP2002529447A (ja) 2002-09-10
DE59908769D1 (de) 2004-04-08
CA2350031C (en) 2010-01-26
AU1153000A (en) 2000-05-29
KR100655632B1 (ko) 2006-12-12
JP4348014B2 (ja) 2009-10-21
HUP0104122A3 (en) 2002-04-29
RU2228330C2 (ru) 2004-05-10
PL347574A1 (en) 2002-04-08
KR20010080385A (ko) 2001-08-22
PL198827B1 (pl) 2008-07-31
CZ302291B6 (cs) 2011-02-09
US6335333B1 (en) 2002-01-01
US6201130B1 (en) 2001-03-13
AR021086A1 (es) 2002-06-12
TR200101245T2 (tr) 2001-10-22
DE19851184A1 (de) 2000-05-11
EP1124797B1 (de) 2004-03-03
CN1332724A (zh) 2002-01-23
HK1041686A1 (en) 2002-07-19
BR9915729A (pt) 2001-10-23
ID28810A (id) 2001-07-05
HUP0104122A2 (hu) 2002-03-28
CA2350031A1 (en) 2000-05-18
WO2000027808A1 (de) 2000-05-18
CZ20011506A3 (cs) 2001-08-15
PT1124797E (pt) 2004-07-30
ATE260889T1 (de) 2004-03-15

Similar Documents

Publication Publication Date Title
CN1280267C (zh) 磺酰氨基羧酸
CN1207056C (zh) 含肽的α-酮酰胺半胱氨酸和丝氨酸蛋白酶抑制剂
CN1149210C (zh) 凝血酶抑制剂
CN1134264C (zh) 抗血栓形成剂
CN1023700C (zh) 芳族及杂环甲酰胺衍生物抗肿瘤剂的制备
CN1165815A (zh) 酚化合物及其制备方法
CN1688548A (zh) 喹啉抗生素中间体的制备方法
CN1228780A (zh) 用作基质金属蛋白酶抑制剂的次膦酸酰胺
CN1198096A (zh) 用于治疗与胶原蛋白过量产生有关的疾病的c-蛋白酶抑制剂
CN1520293A (zh) 作为抗糖尿病药物的3-氟-吡咯烷类
CN1377268A (zh) 细胞粘合抑制剂
CN1072667C (zh) 含咪唑取代基的巯基烷基肽基化合物及其用作基质金属蛋白酶(mmp)和/或肿瘤坏死因子(tnf)抑制剂
CN1040211C (zh) 基质金属蛋白酶抑制剂
CN1131144A (zh) 甘氨酰胺衍生物及其制法和含有它们的药物
CN1066150C (zh) 作为基质金属蛋白酶抑制剂的桥式吲哚
HK1041686A1 (en) N-arylsulfonyl amino acid omega amedes
HK1042691A1 (zh) 磺酰胺异羟肟酸脂
CN1729173A (zh) N-(吲哚乙基)环胺化合物
CN1127488C (zh) 具有生长激素释放特性的化合物
CN1038103A (zh) 环烷基取代的戊二酰胺利尿剂和其制备方法
CN1291197A (zh) 新的乙酰胺衍生物及其用途
CN1212835C (zh) 含异羟肟酸酯的半胱氨酸和丝氨酸蛋白酶抑制剂
CN1425004A (zh) 含杂环侧链的n-取代的金属蛋白酶抑制剂
CN1418210A (zh) 含有碳环侧链的n-取代金属蛋白酶抑制剂
CN1208333C (zh) 主要用于治疗骨质疏松的吲哚衍生物

Legal Events

Date Code Title Description
C06 Publication
C10 Entry into substantive examination
PB01 Publication
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C56 Change in the name or address of the patentee

Owner name: SANOFI- AVENTIS GERMAN CO., LTD.

Free format text: FORMER NAME OR ADDRESS: AVENTIS PHARMACY (GERMANY)INTERNATIONAL CO., LTD.

CP01 Change in the name or title of a patent holder

Address after: Frankfurt, Germany

Patentee after: AVENTIS PHARMA DEUTSCHLAND GmbH

Address before: Frankfurt, Germany

Patentee before: AVENTIS PHARMA DEUTSCHLAND GmbH

C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20050615

Termination date: 20111021